Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Real Obesity Drugs Hurdle: Paying for Them

This article was originally published in RPM Report

Executive Summary

Obesity drugs are readying for round two at FDA. But if ever approved, given the airing of safety issues at advisory committee meetings, who would pay for them?

You may also be interested in...



“Scoring” Savings From Obesity Drugs: CBO Points To Gap Between Categories In Rx Labels And Economic Impact

Proposals to expand Medicare coverage to include obesity therapies are unlikely to be treated as cost-effective by CBO without significant new research on the long term impact of relatively modest changes in BMI. Advocates for coverage may need to focus on other arguments instead.

“Scoring” Savings From Obesity Drugs: CBO Points To Gap Between Categories In Rx Labels And Economic Impact

Proposals to expand Medicare coverage to include obesity therapies are unlikely to be treated as cost-effective by the Congressional Budget Office without significant new research on the long term impact of relatively modest changes in BMI. Advocates for coverage may need to focus on other arguments instead.

Mis-Reading the Minutes: Arena Approval Follows Sell-Off Based on Advisory Committee Summary

Arena received great news June 27: approval of the weight loss therapy Belviq with a very clean label and no special marketing restrictions. That was what Wall Street expected—except when investors read the summary of the advisory committee review of the drug published by FDA on June 22.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS080960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel